News and updates

January 9, 2019

PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk of Recurrence test improves net health outcome for patients and positions the test well for further adoption by health insurance plans in the U.S. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 9 January 2019 – Agendia, Inc., a world leader in precision oncology, announced today…

December 7, 2018

PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 molecular subtype and clarified the biology of HER2 “equivocal” breast cancer46 percent of women under 50 years of age with…

December 5, 2018

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, NETHERLANDS – 28 November 2018 – Agendia, Inc., a world leader in precision oncology, will present new data reinforcing the…

December 4, 2018

PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Helping to Build a Unique Resource for Breast Cancer Research All Oncology Consultants practices participate in the initiative, matching full genome profiles with complete clinical data to create a comprehensive patient database IRVINE, CALIF., U.S., HOUSTON, TEXAS, U.S., AMSTERDAM, NETHERLANDS – 4 December 2018 –…